Gene · 51185
NIH grants1,407
NIH grants whose papers are about the gene, through NIH's grant-paper links.
201 to 220 of 1,407
Download this page as JSON| Grant | Title | CRBN papers | Newest fiscal year |
|---|---|---|---|
| R01CA097098 | Targeting the MUC1-C Oncoprotein in Triple-Negative Breast Cancer | 1 | 2025 |
| R01CA107469 | Role of EZH2 in Breast Cancer Progression | 1 | 2025 |
| R01CA141244 | Allosteric Regulation of MDMX by Protein Disorder | 1 | 2025 |
| R01CA152108 | Molecular and Cellular Mechanisms of Chronic Myelomonocytic Leukemia (CMML) | 1 | 2025 |
| R01CA163915 | ATP-Dependent Chromatin Remodeling in Human Malignancy | 1 | 2025 |
| R01CA173481 | Preclinical analyses of advanced prostate cancer in genetically-engineered mice | 1 | 2025 |
| R01CA183252 | DNMT3A in Development of Hematologic Malignancies | 1 | 2025 |
| R01CA183929 | Molecular mechanisms of prostate cancer metastasis | 1 | 2025 |
| R01CA193837 | Role of ETS factors in specifying prostate luminal cell identity and androgen receptor dependence | 1 | 2025 |
| R01CA193842 | Characterizing the MSI2 network in leukemia | 1 | 2025 |
| R01CA205224 | EEPD1 Repair of Stressed Replication Forks | 1 | 2025 |
| R01CA212608 | Probing RAS-mediated Signaling with Monobody Inhibitors | 1 | 2025 |
| R01CA215226 | Therapeutic Targeting of RNA Splicing in Triple-Negative Breast Cancer | 1 | 2025 |
| R01CA233626 | The function of the PRMT5 methylosome in MTAP deleted cancers | 1 | 2025 |
| R01CA241623 | The Role of Genetic Risk Factors in Keratinocyte Carcinoma Susceptibility | 1 | 2025 |
| R01CA246133 | Targeting tumor-neural cell interactions to inhibit lung cancer brain metastasis | 1 | 2025 |
| R01CA248037 | Regulation of oncogenic Akt ubiquitination and activation by diverse mechanisms in cancer | 1 | 2025 |
| R01CA248112 | BET degraders for improving colorectal cancer therapy | 1 | 2025 |
| R01CA249981 | Mutographs differentiating the inheritance and temporal onset of multiple myeloma | 1 | 2025 |
| R01CA257251 | Targeting CDK6 expression/activity in Ph+ and Ph1-like acute lymphoblastic leukemia (ALL) | 1 | 2025 |
Source NIH's project filesgene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/51185/grants?page=11